Application Value of PET/CT and MRI in the Diagnosis and Treatment of Patients With Synchronous Multiple Pulmonary Ground-Glass Nodules

Shaonan Xie[1], Shaoteng Li[2], Huiyan Deng[3], Yaqing Han[1], Guangjie Liu[1] and Qingyi Liu[1]*

[1] Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China, [2] Department of Diagnostic Radiology, The People's Hospital of Xingtai, Xingtai, China, [3] Department of Pathology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China

Background: Synchronous multiple ground-glass nodules (SMGGNs) in synchronous multiple lung cancers are associated with specific imaging findings. It is difficult to distinguish whether multiple nodules are primary tumors or metastatic lesions in the lungs. The need for PET/CT and contrast-enhanced brain MRI for these patients remains unclear. This study investigated the necessity of these two imaging examinations for SMGGN patients by means of retrospective analysis.

Methods: SMGGN patients who were diagnosed and treated in our hospital from October 2017 to May 2020 and underwent whole-body PET/CT(Cranial excepted) and/ or contrast-enhanced brain MRI+DWI were enrolled in this study. We analyzed the imaging and clinical characteristics of these patients to evaluate SMGGN patients' need to undergo whole-body PET/CT and brain MRI examination.

Results: A total of 87 SMGGN patients were enrolled. 51 patients underwent whole-body PET/CT examinations and did not show signs of primary tumors in other organs, metastatic foci in other organs, or metastasis to surrounding lymph nodes. 87 patients underwent whole-brain MRI, which did not reveal brain metastases but did detect an old cerebral infarction in 23 patients and a new cerebral infarction in one patient. 87 patients underwent surgical treatment in which 219 nodules were removed. All nodules were diagnosed as adenocarcinoma or atypical adenomatous hyperplasia. No lymph node metastasis was noted.

Conclusion: For SMGGN patients, PET/CT and enhanced cranial MRI are unnecessary for SMGGNs patients, but from the perspective of perioperative patient safety, preoperative MRI+DWI examination is recommended for SMGGNs patients.

Keywords: synchronous multiple ground-glass nodules (SMGGNs), positron-emission tomography and computed tomography (PET/CT), magnetic resonance imaging (MRI), lung cancer, adenocarcinoma

INTRODUCTION

The incidence of synchronous multiple lung cancers (SMLCs) accounts for approximately 0.2% of all lung cancers, but the incidence of SMLCs has tended to gradually increase worldwide (1). The reason for this situation may be due to the popularization of low-dose computed tomography (LDCT) and high-resolution CT (HRCT), as well as its promotion and application in early lung cancer screening. Particularly, LDCT and HRCT can be used to find ground-glass nodules (GGNs) in the lungs that cannot be found on traditional chest X-ray (2). However, lung cancer patients with multiple lung lesions have long been difficult to classify due to the inability to distinguish between independent primary tumors and lung cancer with intrapulmonary metastasis, in addition, several patterns of radiological expression are associated with SMLCs (3). To provide better clarity, the 8th edition of the tumor–node–metastasis (TNM) classification for lung cancer developed by the International Association for the Study of Lung Cancer (IASLC) shows that lung cancers that manifest as multiple foci in imaging studies are classified into four categories: secondary primary lung cancer, isolated tumor nodules (intrapulmonary metastasis), multiple GGNs, and pneumonic-type lung adenocarcinoma (4, 5).

The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN guidelines, the 2nd edition, 2020) recommend performing positron-emission tomography/computed tomography (PET/CT) and contrast-enhanced brain magnetic resonance imaging(MRI) for patients with multiple-nodule lung cancer (6). However, the guidelines do not specify anything about the type of multifocal lung cancer. The NCCN guidelines suggest using PET/CT as a preoperative evaluation for patients with multifocal lung cancer to assess whether there is mediastinal lymph node metastasis or distant metastasis (6). Due to the deficiencies of PET/CT in brain imaging, contrast-enhanced brain MRI is used to assess whether patients have neurological metastases (5).

Although the incidence of synchronous multiple GGNs (SMGGNs) has not been quantified, it is becoming more common as one of the imaging manifestations of SMLCs. It is mostly considered to be multiple early primary lung adenocarcinomas or precancerous lesions. Whether patients with SMGGNs can benefit from preoperative PET/CT and brain MRI needs further study. Therefore, to understand the effectiveness and necessity of these modalities in these patients, we conducted a retrospective analysis and evaluation of patients with SMGGNs who underwent routine PET/CT(Cranial excepted) and contrast-enhanced brain MRI+dispersion weighted images sequences(DWI) before surgery to determine whether there was mediastinal lymph node metastasis or organ metastasis, including determining whether SMGGNs were intrapulmonary metastasis.

METHODS

This retrospective study was reviewed and approved by the Ethics Committee of the Fourth Hospital of Hebei Medical University. Since the data of this study are retrospective and anonymous, no informed consent is required.

Enrollment of Patients

SMGGN patients who were diagnosed and treated in the Department of Thoracic Surgery in our hospital from October 2017 to May 2020 and underwent whole-body PET/CT(Cranial excepted) and contrast-enhanced brain MRI+DWI examinations were enrolled in this study. SMGGNs include multiple pure GGNs (pGGNs) and multiple mixed GGNs (mGGNs). pGGNs are seen as focal ground-glass shadows on the lung window on CT, and the nodules must not contain solid components that can block the structure of blood vessels or bronchi (7). mGGNs are GGNs that show up as shadows and contain solid components that block the structure of blood vessels or bronchi. In this study, the patients were selected based on their thin-slice CT images and the above definitions. The CT diagnosis of SMGGNs was defined as two or more GGNs shown on the images in which the maximum diameter of the solid component of mGGNs is not greater than 5 mm. The patients were diagnosed with precancerous lesions or early lung cancer if they had a relevant medical history. Two radiologists and two thoracic surgeons evaluated and compared the CT images longitudinally and reached an agreement on patient enrollment.

Image Acquisition and Analysis

All scanning was performed on a Gemini GXL 16-slice PET/CT system (Philips) with ^{18}F-fluorodeoxyglucose (FDG) (radiochemical identity/purity > 95%) provided by Andico. The patient had fasted for more than 6 hours. The patient's height and weight and level of fasting blood glucose (<6.1 mmol/L) were measured. In the resting state, 222-492.1 MBq (6-13.3 mCi) ^{18}F-FDG was injected via the dorsal vein of the hand. PET/CT was performed 50-60 minutes after injection, during which the patient was resting in a dark room. The patient was in the supine position with both hands on the head. Multislice spiral CT scan was performed first. The scan range was from the neck to the upper segment of the femur. The scan conditions were as follows: voltage 120 kV, current 160 mA, slice thickness 5 mm, interslice gap 5 mm, matrix 512 × 512, helical pitch 0.813, and single rotation time of the tube 0.5 s. The patient was asked to breathe calmly to ensure the scanning images to synchronize with the PET images. Then, the PET scan was performed in the 3D acquisition mode with an acquisition speed of 2.5 min/frame for a total of 8-10 frames. PET images of PET/CT were three-dimensionally reconstructed using the 3D line of response reconstruction algorithm. At the same time, CT data were used for attenuation compensation of the PET images. Both the slice thickness and interslice gap were 5 mm. During a breath-hold, a thin-slice CT scan was carried out on all GGNs in the lungs for reconstruction, with a slice thickness of 0.8 mm. When the pulmonary nodules were suspected of being malignant on PET or CT images, delayed PET scan of the chest was performed 120 minutes after injection of ^{18}F-FDG.

Contrast-enhanced brain MRI was performed by a 1.5- or 3.0-T MRI scanner (GE), with the parameters as follows: axial FSE T2WI/FLAIR (repetition time (TR), 9000 ms; echo time

(TE), 96 ms; number of excitations (NEX), 1; slice thickness, 5 mm), intravenous contrast agent Gd-DTPA (TR, 1700 ms; TE, 2.32 ms; NEX, 1; slice thickness, 5 mm) for axial and sagittal FSE T1WI scanning; DWI sequence (TR, 4100 ms; TE, 64 ms; NEX, 1; slice thickness, 5 mm); and MRA (TR, 22 ms; TE, 3.67 ms; NEX, 1; slice thickness, 5 mm).

Treatment and Pathological Staging

Pathological diagnosis and staging were done in patients undergoing surgical treatment. The postoperative pathological diagnosis was performed according to the standards developed by IASLC/American Thoracic Society/European Respiratory Society classification. Pathological staging was based on the 8th edition of the IASLC lung cancer staging system. Molecular pathological analysis on surgical specimens was performed to investigate the mutation status of the epidermal growth factor receptor (EGFR) gene.

RESULTS

Patient Selection

A total of 109 patients who were diagnosed and treated in the Department of Thoracic Surgery in our hospital from October 2017 to May 2020. 87 patients underwent surgical treatment. All of them underwent enhanced MRI+DWI of the head, and 51 of them underwent whole-body PET/CT(Cranial excepted). All 51 whole-body PET/CT examinations showed no signs of primary tumors in other organs, metastatic foci of other organs, or metastasis to surrounding lymph nodes (no abnormal high FDG uptake was found). All patients underwent contrast-enhanced brain MRI+DWI scan, and it did not reveal brain metastases, though it did detect an old cerebral infarction in 23 patients and new cerebral infarction in one patient by DWI sequences.

22 patients did not undergo surgical treatment. 10 patients' dominant nodules did not meet surgical indications, 3 patients could not tolerate surgery because of underlying disease, and 9 patients refused surgical treatment. All of them underwent whole-body PET/CT(Cranial excepted) too. And All of the whole-body PET/CT examinations showed no signs of primary tumors in other organs, metastatic foci of other organs, or metastasis to surrounding lymph nodes (no abnormal high FDG uptake was found).No patients with SMGGNs abandoned surgery because they were considered for intrapulmonary metastasis (Figure 1).

Characteristics and Imaging Data of the Patient

The median age of the 87 SMGGN patients at onset was 58 years (43-75 years). There were 26 men (29.9%) and 61 women (70.1%). A total of 351 GGNs were observed in the whole group of patients (nodules less than 5 mm were not included). The number of GGNs in each patient was two in 51 patients, 3-5 in 19 patients, 6-10 in 6 patients, and more than 10 in 11 patients. The diameter of the largest nodule on CT was ≤ 10.0 mm in 13 patients, > 10.0 mm and ≤ 20 mm in 42 patients, > 20.0 mm and ≤ 30 mm in 29 patients, and > 30 mm in 3 patients (Table 1).

Surgical and Pathological Outcomes After Surgery

63 patients underwent surgery directly after completing preoperative examination. Of the 23 patients diagnosed with chronic cerebral infarction,14 patients underwent surgery after short-term (7 days) antiplatelet aggregation therapy. 9 patients underwent surgery after cranial MRA and carotid ultrasound to screen blood vessels and control for risk factors. The patient with a new cerebral infarction was treated for cerebral infarction and underwent surgery 6 months later. No cerebrovascular accident occurred in all patients during perioperative period.

A total of 219 GGNs were resected in 87 patients. Postoperative pathology showed invasive adenocarcinoma (AC) in 75 GGNs, minimally invasive adenocarcinoma (MIA) in 47 GGNs, adenocarcinomas in situ (AIS) in 47 GGNs, and atypical adenomatous hyperplasia (AAH) in 50 GGNs. There were no cases of pleural invasion or vascular tumor thrombus, and no metastasis was found in the sampled lymph nodes. One GGN was removed in 19 patients, multiple GGNs were removed from the same lobe in five patients, GGNs in different lobes on the same side were removed in 36 patients, and bilateral GGNs were removed in 27 patients at the same time or in stages. The number of the resected GGNs was one in 19 patients, two in 36 patients, three in 17 patients, four in seven patients, five in four patients, six in one patient, seven in two patients, and nine in one patient (Table 2).

In patients with more than three (including five) GGNs removed, the largest three GGNs were tested for EGFR gene mutation. Among the 68 patients with multiple GGNs removed, 57 patients had one of various EGFR mutations (83.8%, 57/68) in their lung GGNs (Figure 2).

DISCUSSION

We conducted this retrospective analysis to evaluate the necessity of preoperative whole-body PET/CT and contrast-enhanced brain MRI in patients with SMGGNs. Although false-positive uptake of ^{18}F-FDG is often seen in daily PET/CT studies (8), none of our 51 patients undergoing PET/CT had other primary or secondary lesions in distant organs or metastasis to mediastinal lymph nodes. In all patients undergoing surgery, no metastatic lymph nodes were found in postoperative pathological examination. The preoperative screening section of the NCCN Guidelines for non-small cell lung cancer in the United States recommends that patients with SMLC undergo a whole-body PET/CT and a contrast-enhanced MRI examination of the head before surgery (9). For patients with multiple pGGNs, whether these two examinations are required before surgery is inconclusive, and no scientific consensus has been reached.

On CT images, lung nodules can be divided into solid nodules (SNs), part-solid nodules (PSNs) or mGGNs, and nonsolid nodules or pGGNs. Both pGGNs/NSNs and mGGNs/PSNs are called subsolid nodules (SSNs) (10–12). We added an additional high-resolution CT scan at breath-hold for patients who had GGNs identified on the thin-slice CT in the subsequent PET/CT scan, so the diagnosis of pGGN is reliable.

Lung GGNs that persist in CT scans is considered an imaging manifestation of early lung adenocarcinoma or precancerous

FIGURE 1 | Flow chat of SMGGN patient enrollment and examination.

lesions (13). According to the new lung adenocarcinoma staging system (4), GGNs can show a growth pattern of attachment to the alveolar wall under the microscope. This indicates a lower invasiveness. This growth pattern has little effect on alveolar ventilation. This feature of GGNs can be observed on CT images (14). The 219 nodules we resected were pathologically diagnosed as invasive adenocarcinoma, minimally invasive adenocarcinoma, adenocarcinoma *in situ*, or lung atypical adenomatous hyperplasia after surgery. Lung adenocarcinoma is the most common pathological type of lung cancer and is associated with mutations in a variety of oncogenes. The most commonly mutated genes include *EGFR*, *ALK*, *BRAF*, and *KRAS*. We performed *EGFR* mutation detection on 187 of these nodules, and 109 *EGFR* mutations were detected, for a mutation rate of 58.3%.

The cause of GGNs still needs to be investigated. GGNs are somewhat different from typical lung cancer. There is no obvious relationship between the occurrence of GGNs and smoking (a carcinogen). Most GGN patients do not smoke. The occurrence and development of GGNs are relatively slow, mostly in the peripheral part of the lung, and multiple primary lesions may be present. Household air pollution may be related to the incidence

of GGNs. Household air pollution includes exhaust gas from burning solid fuels for heating and cooking and oil fumes that come from cooking (15). In our study, females (61/87) and nonsmoking patients (69/87) patients accounted for most of the enrolled patients.

Like other SMLCs, SMGGNs cause confusion for clinicians. It is hard to tell whether an SMGGNs are a lung metastasis of the same primary cancer or are multiple primary lung cancers (MPLCs) of different origins. Moreover, this confusion has not been resolved by advancements in pathology, because the SMGGNs usually have the same histological type, even if they have different growth patterns (16). According to the traditional definition, MPLCs with the same histological results must be evaluated according to the following criteria: 1. The histological origin is carcinoma *in situ*. 2. No lymph nodes in the conventional lymph node metastasis pathways are involved. 3. There is no extrathoracic metastasis (17, 18). In our study, we found no signs of metastasis on any PET/CT images, including lymph node metastasis and organ metastasis. These findings confirm that the multiple pGGNs were MPLCs with multiple primary lesions. In the Fleischner Society and IASLC statements, SMGGNs are considered to be the early stages of MPLC.

TABLE 1 | Clinical characteristics of 87 patients.

Variable/characteristic	Result/No. of patients (%)
Median age, years	58 (range, 43-75)
Sex	
Male	26 (29.9)
Female	61 (70.1)
Smoking history	
Yes	18 (20.7)
No	69 (79.3)
Initial symptoms	
Asymptomatic	69 (79.3)
Cough	14 (16.1)
Other symptoms	4 (4.6)
No. of GGNs per patient	477
2	51 (58.6)
3-5	19 (21.8)
6-10	6 (6.9)
>10	11 (12.6)
Tumor size of dominant lesion on CT	
≤10 mm	13 (14.9)
>10 mm, ≤20 mm	42 (48.3)
>20 mm, ≤30 mm	29 (33.3)
>30 mm	3 (3.4)
Average SUV_{max} of dominant lesion on PET/CT	1.1

TABLE 2 | Pathological and molecular-biological characteristics of 87 patients.

Variable/characteristic	Result/No. of patients (%)
Surgical procedure	87 (100)
pGGNs resected	219
Operation	
Ipsilateral	60 (69.0)
Bilateral	27 (31.0)
Histological type (219 pGGNs)	
AAH	50 (22.8)
AIS	47 (21.5)
MIA	47 (21.5)
AC	75 (34.2)
Pathological lymph nodal metastasis	
No (N_0)	87 (100)
Yes (N_{1-2})	0 (0)
Molecular pathology (194 pGGNs)	
EGFR wild-type	78 (42.7)
EGFR mutated	109 (58.3)
21L858R	54 (27.8)
21L861Q	3 (1.5)
19deletion	44 (22.7)
18G719X	2 (1.0)
20T790M	2 (1.0)
20S768I	1 (0.5)
21L858R+2L62R	1 (0.5)
21L858R+20T790M	1 (0.5)
19deletion+21L858R	1 (0.5)

In addition to identifying and classifying SMGGNs based on histopathological findings, researchers and clinicians have also used molecular biology methods. The molecular biology test results of tissue specimens strongly support the view that they are all independent primary tumors (19, 20). In our study, among the 68 patients with multiple nodules removed, 57 patients had lung nodules with *EGFR* mutation status (83.8%, 57/68), confirming the above results. Base on this, we believe that we believe that for a molecular biology point of view, all SMGGNs are independent primary tumors, it is invalid to use PET/CT to determine whether the SMGGNs are metastatic nodules or to look for other primary tumor. However, Li et al. (21) published an article about the occurrence of intrapulmonary metastases in the form of multiple GGNs. They performed whole-exome sequencing on each of the removed nodules in two patients with multiple GGNs in the lungs. They found in each of these two patients that two GGNs shared multiple rare nonsynonymous and synonymous mutations, which strongly suggested that they were intrapulmonary metastases. In contrast, the remaining GGNs showed different clonal origins. The reason for the early metastasis of GGNs may be the dissemination of tumor cells in the alveolar cavity. Although this new metastasis model of lung cancer has been well accepted, whether there are metastases in multiple GGNs in the lungs, especially multiple GGNs in the bilateral lungs, still needs to be studied and verified.

Lesions (including single lesions and multiple lesions) that appear as pure GGNs on CT images and tumors with growth patterns of attachment to the wall show indolent biological behavior and are associated with a relatively good prognosis (22, 23). Based on the multiple origins of multiple GGNs in the lungs confirmed by our research and the absence of lymph node metastasis, we have reason to believe that for patients with multiple GGNs in the lungs, limited lung resection with close follow-up should be recommended over lobectomy to observe the remaining nodules after surgery. This is the best diagnostic and treatment strategy for patients with multiple GGNs in the lung. Next-generation gene sequencing technology can be used for whole-genome sequencing, whole-exome sequencing, or target gene sequencing on surgically resected specimens to analyze whether multiple GGNs have the same origin (24). This is necessary for the overall management of the disease in patients with multiple GGNs.

It has been report (25, 26) that the sensitivity of crania enhanced MRI in screening for brain metastasis of lung cancer is not inferior to or even higher than that of whole-body PET/CT, so in our study cranial enhanced MRI was used to screen for intracranial metastasis. Although the preoperative MRI of all 87 patients did not show intracranial metastases, but combined with DWI sequence, it did reveal an old cerebral infarction in 23 patients and a new cerebral infarction in one patient. The new onset of cerebral infarction indicates the patient is in a period of hemodynamic instability, so cerebrovascular accident is more likely to recur during the perioperative period after video-assisted thoracoscopic lung resection (27). Patients with old cerebral infarction and abnormal cerebrovascular stenosis are more likely to have cerebrovascular accidents when undergoing lung (especially upper lobe) resection than the healthy population (28). Compared with PET/CT, head MRI+DWI has significant advantages in the diagnosis of cerebral infarction (29). Therefore, we believe that for patients with multiple GGNs, preoperative contrast-enhanced brain MRI is necessary.

This study has some limitations. First, the sample size of this study was relatively small. The high cost of PET/CT examinations made it hard to enroll many cases. Second, the study is limited by its retrospective design, which may have caused selection bias.

FIGURE 2 | The distribution of EGFR mutations in 87 patients.

Prospective studies should evaluate the practicality of preoperative PET/CT and brain MRI. Finally, we only included patients with multiple pGGNs and mGGNs with solid components ≤ 5 mm and excluded patients with mGGNs with solid components > 5 mm. Since mGGNs with a solid component > 5 mm are more invasive, PET/CT and brain MRI in SMGGNs of patients with a solid component > 5 mm before surgery require further study.

CONCLUSION

Whole-body PET/CT and contrast-enhanced brain MRI didn't provide additional information to determine whether patients with SMGGNs had intrapulmonary metastases and the presence of lymph node and organ metastases., but the DWI sequence can help us find some surgical risk factors before surgery, screen some patients who are not suitable for surgery, and intervene in advance for those patients who still have the chance of surgery, so as to reduce the perioperative surgical risk of patients. Based on the results of our study, we believe that PET/CT and enhanced cranial MRI are unnecessary for SMGGNs patients, but from the perspective of perioperative patient safety, preoperative MRI+DWI examination is recommended for SMGGNs patients. Of course, this conclusion is based on our retrospective study, and we expect RCT studies to prove this conclusion.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/**Supplementary Material**. Further inquiries can be directed to the corresponding author.

ETHICS STATEMENT

Ethical review and approval was not required for the study on human participants in accordance with the local legislation and institutional requirements. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements. Written informed consent was not obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

AUTHOR CONTRIBUTIONS

FUNDING

ACKNOWLEDGMENTS

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2022.797823/full#supplementary-material

REFERENCES

1. Jung EJ, Lee JH, Jeon K, Koh WJ, Suh GY, Chung MP, et al. Treatment Outcomes for Patients With Synchronous Multiple Primary Non-Small Cell Lung Cancer. *Lung Cancer* (2011) 73(2):237–42. doi: 10.1016/j.lungcan.2010.11.008

2. Henschke CI, Yip R, Shaham D, Zulueta JJ, Aguayo SM, Reeves AP, et al. The Regimen of Computed Tomography Screening for Lung Cancer: Lessons Learned Over 25 Years From the International Early Lung Cancer Action Program. *J Thorac Imaging* (2020) 36:6–23. doi: 10.1097/RTI.0000000000000538

3. Yu YC, Huang CS, Huang BS. Separate or Intrapulmonary Metastasis. *J Thorac Dis* (2018) 10(Suppl 26):S3128–30. doi: 10.21037/jtd.2018.08.74

4. Detterbeck FC, Nicholson AG, Franklin WA, Marom EM, Travis WD, Girard N, et al. The IASLC Lung Cancer Staging Project: Summary of Proposals for Revisions of the Classification of Lung Cancers With Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification. *J Thorac Oncol* (2016) 11(5):639–50. doi: 10.1016/j.jtho.2016.01.024

5. Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT. The Eighth Edition Lung Cancer Stage Classification. *Chest* (2017) 151(1):193–203. doi: 10.1016/j.chest.2016.10.010

6. Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, et al. Non-Small Cell Lung Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw* (2020) 15(4):504–35. doi: 10.6004/jnccn.2021.0013

7. Callister ME, Baldwin DR, Akram AR, Barnard S, Cane P, Draffan J, et al. British Thoracic Society Guidelines for the Investigation and Management of Pulmonary Nodules. *Thorax* (2015) 70(Suppl 2):ii1–54. doi: 10.1136/thoraxjnl-2015-207168

8. Bustos García de Castro A, Ferreirós Domínguez J, Delgado Bolton R, Fernández Pérez C, Cabeza Martínez B, García García-Esquinas M, et al. PET/CT in Presurgical Lymph Node Staging in Non-Small Cell Lung Cancer: The Importance of False-Negative and False-Positive Findings. *Radiologia* (2017) 59(2):147–58. doi: 10.1016/j.rx.2016.12.001

9. Kalemkerian GP, Loo BW, Akerley W, Attia A, Bassetti M, Boumber Y, et al. NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018. *J Natl Compr Canc Netw* (2018) 16(10):1171–82. doi: 10.6004/jnccn.2018.0079

10. Kim TJ, Kim CH, Lee HY, Chung MJ, Shin SH, Lee KJ, et al. Management of Incidental Pulmonary Nodules: Current Strategies and Future Perspectives. *Expert Rev Respir Med* (2020) 14(2):173–94. doi: 10.1080/17476348.2020.1697853

11. Raad RA, Suh J, Harari S, Naidich DP, Shiau M, Ko JP. Nodule Characterization: Subsolid Nodules. *Radiol Clin North Am* (2014) 52(1):47–67. doi: 10.1016/j.rcl.2013.08.011

12. Truong MT, Ko JP, Rossi SE, Rossi I, Viswanathan C, Bruzzi JF, et al. Update in the Evaluation of the Solitary Pulmonary Nodule. *Radiographics* (2014) 34(6):1658–79. doi: 10.1148/rg.346130092

13. Kim HY, Shim YM, Lee KS, Han J, Yi CA, Kim YK. Persistent Pulmonary Nodular Ground-Glass Opacity at Thin-Section CT: Histopathologic Comparisons. *Radiology* (2007) 245(1):267–75. doi: 10.1148/radiol.2451061682

14. Rossi G, Nappi O. What's New in the WHO Classification of Tumors of Lung and Pleura. *Pathologica* (2018) 110(1):3–4.

15. Hosgood HD3rd, Song M, Hsiung CA, Yin Z, Shu XO, Wang Z, et al. Interactions Between Household Air Pollution and GWAS-Identified Lung Cancer Susceptibility Markers in the Female Lung Cancer Consortium in Asia (FLCCA). *Hum Genet* (2015) 134(3):333–41. doi: 10.1007/s00439-014-1528-z

16. Homer RJ. Pathologists' Staging of Multiple Foci of Lung Cancer: Poor Concordance in Absence of Dramatic Histologic or Molecular Differences. *Am J Clin Pathol* (2015) 143(5):701–6. doi: 10.1309/AJCPNBWF55VGKOIW

17. Shinozaki-Ushiku A, Kohsaka S, Kage H, Oda K, Miyagawa K, Nakajima J, et al. Genomic Profiling of Multiple Primary Cancers Including Synchronous Lung Adenocarcinoma and Bilateral Malignant Mesotheliomas: Identification of a Novel BAP1 Germline Variant. *Pathol Int* (2020) 70:775–80. doi: 10.1111/pin.12977

18. Kozower BD, Larner JM, Detterbeck FC, Jones DR. Special Treatment Issues in non-Small Cell Lung Cancer: Diagnosis and Management of Lung Cancer, 3rd Ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* (2013) 143(5 Suppl):e369S–99S. doi: 10.1378/chest.12-2362

19. Liu M, He WX, Song N, Yang Y, Zhang P, Jiang GN. Discrepancy of Epidermal Growth Factor Receptor Mutation in Lung Adenocarcinoma Presenting as Multiple Ground-Glass Opacities. *Eur J Cardiothorac Surg* (2016) 50(5):909–13. doi: 10.1093/ejcts/ezw113

20. Chung JH, Choe G, Jheon S, Sung SW, Kim TJ, Lee KW, et al. Epidermal Growth Factor Receptor Mutation and Pathologic-Radiologic Correlation Between Multiple Lung Nodules With Ground-Glass Opacity Differentiates Multicentric Origin From Intrapulmonary Spread. *J Thorac Oncol* (2009) 4(12):1490–5. doi: 10.1097/JTO.0b013e3181bc9731

21. Li R, Li X, Xue R, Yang F, Wang S, Li Y, et al. Early Metastasis Detected in Patients With Multifocal Pulmonary Ground-Glass Opacities (GGOs). *Thorax* (2018) 73(3):290–2. doi: 10.1136/thoraxjnl-2017-210169

22. Lee HW, Jin KN, Lee JK, Kim DK, Chung HS, Heo EY, et al. Long-Term Follow-Up of Ground-Glass Nodules After 5 Years of Stability. *J Thorac Oncol* (2019) 14(8):1370–7. doi: 10.1016/j.jtho.2019.05.005

23. Lee JH, Park CM, Lee SM, Kim H, McAdams HP, Goo JM. Persistent Pulmonary Subsolid Nodules With Solid Portions of 5 Mm or Smaller:

Their Natural Course and Predictors of Interval Growth. *Eur Radiol* (2016) 26 (6):1529–37. doi: 10.1007/s00330-015-4017-4

24. Saab J, Zia H, Mathew S, Kluk M, Narula N, Fernandes H. Utility of Genomic Analysis in Differentiating Synchronous and Metachronous Lung Adenocarcinomas From Primary Adenocarcinomas With Intrapulmonary Metastasis. *Transl Oncol* (2017) 10(3):442–9. doi: 10.1016/j.tranon.2017.02.009

25. Lee HY, Lee KS, Kim BT, Cho YS, Lee EJ, Yi CA, et al. Diagnostic Efficacy of PET/CT Plus Brain MR Imaging for Detection of Extrathoracic Metastases in Patients With Lung Adenocarcinoma. *J Korean Med Sci* (2009) 24(6):1132–8. doi: 10.3346/jkms.2009.24.6.1132

26. Ohno Y, Koyama H, Nogami M, Takenaka D, Yoshikawa T, Yoshimura M, et al. Whole-Body MR Imaging vs. FDG-PET: Comparison of Accuracy of M-Stage Diagnosis for Lung Cancer Patients. *J Magn Reson Imaging* (2007) 26 (3):498–509. doi: 10.1002/jmri.21031

27. Wang Z, Zhang J, Cheng Z, Li X, Wang Z, Liu C, et al. Factors Affecting Major Morbidity After Video-Assisted Thoracic Surgery for Lung Cancer. *J Surg Res* (2014) 192(2):628–34. doi: 10.1016/j.jss.2014.07.051

28. Matsumoto K, Sato S, Okumura M, Niwa H, Hida Y, Kaga K, et al. Left Upper Lobectomy Is a Risk Factor for Cerebral Infarction After Pulmonary Resection: A Multicentre, Retrospective, Case-Control Study in Japan. *Surg Today* (2020) 50:1383–92. doi: 10.1007/s00595-020-02032-4

29. Zhang MJ, Zhang X, Xu YX. Analysis on Value of CT and MRI Clinical Application in Diagnosis of Middle-Aged Patients With Multiple Cerebral Infarction. *Int J Clin Exp Med* (2015) 8(10):17123–7.